MedTrace Logo

Riboflavin-UVA Induced Collagen Crosslinking Treatment for Corneal Ectasia

NCT01123057 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-05-14

No results posted yet for this study

Summary

This is a hospital-based interventional prospective study. Patients with clinical keratoconus or LASIK keratectasia presenting to the Singapore National Eye Centre who meet the eligibility criteria are recruited for this study. The aim of the study is to assess the safety and efficacy of riboflavin-UVA induced cross-linking treatment for corneal ectasia

Conditions

  • Corneal Ectasia

Interventions

PROCEDURE

riboflavin-induced collagen cross-linking treatment

The principle of the procedure is to induce collagen crosslinking of the corneal stroma by the using riboflavin/UVA-treatment. The technique involves topical application of riboflavin/dextran solution onto eye after removal of corneal epithelium. After initial riboflavin application for 30 minutes, UVA light is shone onto the cornea for another 30 minutes with continued topical riboflavin application.

DEVICE

Riboflavin-UVA induced collagen cross-linking treatment for corneal ectasia

Use of riboflavin eyedrops during the procedure Use of UVA device (Peschke Meditrade)

Sponsors & Collaborators

  • Singapore National Eye Centre

    lead OTHER_GOV

Principal Investigators

  • Li Lim · Singapore National Eye Centre

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01123057 on ClinicalTrials.gov